Analyst consensus rating
Chemomab Therapeutics Analyst Rating: Buy
CMMB is rated Buy by 1 analysts with a $5.00 target. As of 2026-08-29.
Direct answer
Chemomab Therapeutics's consensus rating is Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.00.
Forecast evidence checked August 29, 2026.
Get free Chemomab Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.71
- Average price target
- $5.00
- High price target
- $5.00
- Low price target
- $5.00
- Low target gap
- +84.5%
- Target upside
- +84.5%
- High target gap
- +84.5%
- Target range width
- 0%
- Consensus rating
- Buy
- Analysts
- 1
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Chemomab Therapeutics?
Chemomab Therapeutics has a verified Buy consensus. The same dataset has an average price target of $5.00.
How far are Chemomab Therapeutics's low and high targets from the recorded price?
The low target implies +84.5%, while the high target implies +84.5%.
How many analysts are included in Chemomab Therapeutics's consensus?
The verified consensus includes 1 analysts.
How is Chemomab Therapeutics's target upside or downside calculated?
The average target of $5.00 is divided by the recorded price of $2.71, then one is subtracted to produce +84.5%. This does not guarantee a future return.
When was Chemomab Therapeutics's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.